Marinus Pharmaceuticals (NASDAQ:MRNS) Given "Overweight" Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS - Free Report) in a research report released on Wednesday morning, Benzinga reports. The firm currently has a $28.00 target price on the biopharmaceutical company's stock.

A number of other research analysts have also recently weighed in on MRNS. HC Wainwright restated a buy rating and issued a $27.00 price objective on shares of Marinus Pharmaceuticals in a report on Tuesday, March 26th. Oppenheimer restated a market perform rating and set a $9.00 target price on shares of Marinus Pharmaceuticals in a research note on Thursday, March 7th. Royal Bank of Canada reiterated an outperform rating and set a $24.00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, March 6th. Finally, StockNews.com lowered shares of Marinus Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Marinus Pharmaceuticals currently has a consensus rating of Moderate Buy and a consensus target price of $21.21.

Marinus Pharmaceuticals Trading Down 3.5 %

NASDAQ MRNS traded down $0.29 on Wednesday, reaching $8.09. The stock had a trading volume of 671,287 shares, compared to its average volume of 455,553. The company has a quick ratio of 4.01, a current ratio of 4.07 and a debt-to-equity ratio of 5.68. The stock has a fifty day moving average price of $9.36 and a two-hundred day moving average price of $8.59. Marinus Pharmaceuticals has a 12-month low of $5.57 and a 12-month high of $11.26. The firm has a market capitalization of $444.38 million, a price-to-earnings ratio of -3.07 and a beta of 0.91.

Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. The firm had revenue of $7.19 million during the quarter, compared to analysts' expectations of $7.78 million. During the same quarter in the prior year, the firm posted ($0.76) EPS. As a group, sell-side analysts forecast that Marinus Pharmaceuticals will post -2.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Ameritas Investment Partners Inc. acquired a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at approximately $45,000. Quantbot Technologies LP purchased a new stake in shares of Marinus Pharmaceuticals in the first quarter valued at about $40,000. FMR LLC raised its holdings in shares of Marinus Pharmaceuticals by 1,887.9% in the first quarter. FMR LLC now owns 4,433 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 4,210 shares during the last quarter. BluePath Capital Management LLC acquired a new stake in shares of Marinus Pharmaceuticals during the third quarter worth about $38,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of Marinus Pharmaceuticals by 383.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,307 shares of the biopharmaceutical company's stock worth $69,000 after buying an additional 5,003 shares during the last quarter. Hedge funds and other institutional investors own 98.80% of the company's stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.